409 related articles for article (PubMed ID: 22056763)
1. Roles of PPARs in NAFLD: potential therapeutic targets.
Tailleux A; Wouters K; Staels B
Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
[TBL] [Abstract][Full Text] [Related]
2. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
3. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
6. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.
Silva AKS; Peixoto CA
Cell Mol Life Sci; 2018 Aug; 75(16):2951-2961. PubMed ID: 29789866
[TBL] [Abstract][Full Text] [Related]
7. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
9. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
10. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
11. PPARs and nonalcoholic fatty liver disease.
Liss KH; Finck BN
Biochimie; 2017 May; 136():65-74. PubMed ID: 27916647
[TBL] [Abstract][Full Text] [Related]
12. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.
Gross B; Pawlak M; Lefebvre P; Staels B
Nat Rev Endocrinol; 2017 Jan; 13(1):36-49. PubMed ID: 27636730
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between PPARs and gut microbiota in NAFLD.
Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
[TBL] [Abstract][Full Text] [Related]
14. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X; Zhang Y; Xie M
Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
[TBL] [Abstract][Full Text] [Related]
15. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Francque S; Szabo G; Abdelmalek MF; Byrne CD; Cusi K; Dufour JF; Roden M; Sacks F; Tacke F
Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):24-39. PubMed ID: 33093663
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
19. The Role of PPARs in Disease.
Wagner N; Wagner KD
Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
[TBL] [Abstract][Full Text] [Related]
20. Host genetic variants in obesity-related nonalcoholic fatty liver disease.
Mehta R; Birerdinc A; Younossi ZM
Clin Liver Dis; 2014 Feb; 18(1):249-67. PubMed ID: 24274878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
